Edition:
United States

Emergent BioSolutions Inc (EBS.N)

EBS.N on New York Stock Exchange

33.61USD
12:32pm EDT
Change (% chg)

$0.37 (+1.11%)
Prev Close
$33.24
Open
$33.03
Day's High
$33.80
Day's Low
$32.82
Volume
27,483
Avg. Vol
134,242
52-wk High
$44.29
52-wk Low
$27.01

EBS.N

Chart for EBS.N

About

Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of... (more)

Overall

Beta: 1.29
Market Cap(Mil.): $1,331.62
Shares Outstanding(Mil.): 40.06
Dividend: --
Yield (%): --

Financials

  EBS.N Industry Sector
P/E (TTM): 18.01 41.28 37.71
EPS (TTM): 1.85 -- --
ROI: 9.91 -9.20 14.43
ROE: 14.67 -9.24 15.61

BRIEF-Emergent Biosolutions to repurchase shares for up to $50 mln

* Emergent Biosolutions to implement stock repurchase program for up to $50 million of its common stock

Jul 15 2016

BRIEF-FDA Accepts Emergent BioSolutions' supplemental biologics license application for large-scale manufacturing of BioThrax in Building 55

* FDA has set a prescription drug user fee act (PDUFA) target action date of august 15, 2016

Jun 17 2016

BRIEF-Emergent Biosolutions Inc receives FDA orphan drug status for BioThrax

* Emergent BioSolutions Inc receives FDA orphan drug status for BioThrax for post-exposure prophylaxis of anthrax disease

Jun 15 2016

BRIEF-Emergent Biosolutions reports Q1 GAAP earnings per share $0.10

* Emergent biosolutions reports first quarter 2016 financial results

May 05 2016

BRIEF-Emergent Biosolutions submits application for large scale manufacturing of biothrax

* Submits Sbla For Fda Approval Of Large Scale manufacturing of biothrax in building 55

Apr 18 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.